PMC8216418_01
PMC8216418_02
SOUTH: study on outcomes related to tuberculosis and HIV drug concentrations in Uganda, MDR-TB: multidrug-resistant tuberculosis, R: rifampicin, H: isoniazid, Z: pyrazinamide, E: ethambutol, Km: kanamycin, Lef: levofloxacin, Cs: cycloserine, Eto: ethionamide, Pza: pyrazinamide. If not otherwise stated, the numbers preceding the anti-TB drugs refer to the number of months (e.g. 3RHZE means 3 months of RHZE).
10.1177_2050313X211019790-fig1.jpg
PMC8216418_02_10.1177_2050313X211019790-fig1.jpg
fig1-2050313X211019790
The other patients were treated with adapted combinations of first-line anti-TB drugs, but none of them according to the WHO treatment guidelines applicable at that time (see Figure 1).
PMC8216418_03
PMC8216418_04
PMC8216418_05
PMC8216418_06
PMC8216418_07